Document is current
Any future updates will be listed below
-
Authors
Modi, Shanu https://orcid.org/0000-0001-6427-7373
Jacot, William https://orcid.org/0000-0001-7834-061X
Iwata, Hiroji
Park, Yeon Hee
Vidal Losada, Maria https://orcid.org/0000-0003-1992-5727
Li, Wei
Tsurutani, Junji https://orcid.org/0000-0002-6260-6943
Ueno, Naoto T. https://orcid.org/0000-0002-0166-7275
Zaman, Khalil https://orcid.org/0000-0002-2997-527X
Prat, Aleix https://orcid.org/0000-0003-2377-540X
Papazisis, Konstantinos
Rugo, Hope S. https://orcid.org/0000-0001-6710-4814
Yamashita, Toshinari
Harbeck, Nadia https://orcid.org/0000-0002-9744-7372
Im, Seock-Ah https://orcid.org/0000-0002-5396-6533
De Laurentiis, Michelino https://orcid.org/0000-0001-9009-1572
Pierga, Jean-Yves
Wang, Xiaojia https://orcid.org/0000-0002-7005-0842
Gombos, Andrea
Tokunaga, Eriko
Orbegoso Aguilar, Cecilia
Yung, Lotus
Xiao, Feng
Cheng, Yingkai
Cameron, David https://orcid.org/0000-0002-2717-7979
- License Information
-
More Information
Article History
Received: 12 March 2025
Accepted: 27 August 2025
First Online: 8 October 2025
Competing interests
: The authors declare the following competing interests: S.M. has received grants from Genentech, AstraZeneca, Seattle Genetics, Pfizer, Daiichi Sankyo, Duality Bio, D3 Bio, Nuvation Bio and BioNTech; has received consulting fees and/or honoraria from Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Macrogenetics, GlaxoSmithKline, Seattle Genetics, Pfizer, Bristol Myers Squib, Nuvation Bio, D3 Bio, AstraZeneca, BioNTech, Boehringer Ingelheim and Avacta. W.J. has received grants from Daiichi Sankyo and AstraZeneca; has received support for attending meetings and/or travel from AstraZeneca, Eisai, Lilly France, Pfizer, Roche, Chugai Pharma, GlaxoSmithKline, Novartis, Pierre Fabre and Sanofi Aventis; has participated on a data safety monitoring or advisory board for Daiichi Sankyo, AstraZeneca, Eisai, Lilly France, Pfizer, Roche, BMS, Novartis, MSD, Seagen and Gilead. H.I. has received grants from Daiichi Sankyo, AstraZeneca and Chugai; has received consulting fees from Daiichi Sankyo, AstraZeneca, Chugai, Lilly, MSD, Pfizer and Gilead; has received honoraria from Daiichi Sankyo, AstraZeneca, Chugai, Lilly, MSD, Pfizer, Taiho and Kyowa Kirin. Y.H.P. has received grants from AstraZeneca, Pfizer, Novartis, MSD, Roche, Gencurix and GenomeInsight; has received consulting fees from Daiichi Sankyo, AstraZeneca, Pfizer, Roche, Eisai, Gilead, MSD, Novartis and Lilly; has received honoraria from Daiichi Sankyo, AstraZeneca, Pfizer, MSD, Novartis, Roche and Gilead; has received support for attending meetings and/or travel from Gilead and MSD; has participated on data safety monitoring or advisory boards for Daiichi Sankyo, AstraZeneca, Roche, Eisai, Gilead, MSD, Novartis and BeiGene. M.V.L. has received honoraria from Daiichi Sankyo, Roche, Novartis and Pfizer; has received support for attending meetings and/or travel from Roche and Pfizer; has participated on data safety monitoring or advisory boards for Novartis and Roche. J.T. has received grants from Daiichi Sankyo and Eli Lilly; has received consulting fees from Daiichi Sankyo and AstraZeneca; has received honoraria from Daiichi Sankyo, AstraZeneca, Eli Lilly and Kyowa Kirin; has led or had a fiduciary role in the West Japan Oncology Group. N.T.U. has received consulting fees from AstraZeneca, Bayer AG, Bristol Myers Squibb, Carna Biosciences, CytoDyn, Daiichi Sankyo, Eisai Co, Eli Lilly, Genentech, Genomic Health, Gilead Sciences, Lavender Health, OncoCyte Corporation, Pear Bio, Peptilogics, Pfizer, Phoenix Molecular Designs, Preferred Medicine, Carisma Therapeutics, Sysmex Corporation, Takeda and Unitech; has stock in Pear Bio and Phoenix Molecular Designs; has had a speaker or preceptorship role with AstraZeneca, Chugai Roche, Daiichi Sankyo, Kyowa Kirin, Pfizer, Total Health Conferencing and Eli Lilly; has research agreements with AnHeart Therapeutics, Eisai, Gilead Sciences, Phoenix Molecular Designs, Daiichi Sankyo, Puma Biotechnology, Merck, Oncolys BioPharma, OBI Pharma, ChemDiv, Tolero Pharmaceuticals and VITRAC Therapeutics. K.Z. has received grants from Roche; has received honoraria from Daiichi Sankyo, AstraZeneca, MSD, Exact Sciences, Lilly, Pierre Fabre, Gilead, Novartis, Pfizer, Roche and Seagen; has received support for attending meetings and/or traveling from Daiichi Sankyo, AstraZeneca, Gilead, Pfizer, Pierre Fabre and Roche; has participated on data safety monitoring or advisory boards for Daiichi Sankyo, AstraZeneca, Exact Sciences, Gilead, Novartis, Lilly, MSD, Pierre Fabre, and Seagen; is part of the steering committee of an international trial for Daiichi Sankyo and Pierre Fabre; is part of the independent data-monitoring committee for an international trial for Roche. A.P. has received grants from Daiichi Sankyo, AstraZeneca, Boehringer, Novartis, Roche, Pfizer, Lilly and Reveal Genomics; has received consulting fees from Daiichi Sankyo, AstraZeneca, Roche, Pfizer, Novartis, Puma, Peptomyc, Reveal Genomics and Ona Therapeutics; has received honoraria from Daiichi Sankyo, Roche, Pfizer and Novartis; has the following patents: CES WO/2018/096191, ERBB2 WO2018/103834A1 (issued), DNADX (pending), HER2DX (pending) and TNBCDX (pending); has a leadership or fiduciary role in Reveal Genomics; has stock or stock options in Reveal Genomics and Ona Therapeutics; is on the board of directors for Reveal Genomics. K.P. has received grants from Daiichi Sankyo, AstraZeneca, Merck, Novartis, Primeview, GSK, BMS, Boehringer Ingelheim, IQVIA, Health Data Specialists AE, MSD, Roche, PPD, Lilly, Gilead, Genesis, Sanofi and Value Research AE; has received consulting fees from Novartis, Gilead, MSD, Lilly and Primeview; has received honoraria from AstraZeneca, MSD, Novartis, Roche, Gilead, Ipsen, Lilly, Pharmabide and Genesis; has received support for attending meetings and/or travel from AstraZeneca, DEMO, MSD, Novartis, Roche, Gilead and Genesis. H.S.R. has received grants from Daiichi Sankyo, AstraZeneca, F. Hoffmann-La Roche Genentech, Gilead Sciences, Lilly, Merck, Novartis, Pfizer, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics and OBI Pharma; has received consulting fees from Daiichi Sankyo, Mylan, Viatris, NAPO and Puma. T.Y. has received grants from Daiichi Sankyo, AstraZeneca, Chugai, Taiho, Nippon Kayaku, Eli Lilly, Pfizer, Seagen, MSD and Kyowa Kirin; has received honoraria from Daiichi Sankyo, AstraZeneca, Chugai, Eisai, Novartis Pharma, Taiho, Nippon Kayaku, Kyowa Kirin, Pfizer and Eli Lilly. N.H. has received consulting fees from Gilead, Roche, Sandoz, Sanofi and Seagen; has received honoraria from Daiichi Sankyo, AstraZeneca, Amgen, EPG Communication, Gilead, Lilly, MEDSCAPE, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi, Seagen, Springer, Viatris and Zuelligpharma; has participated on a data safety monitoring or advisory board for Roche; has a leadership or fiduciary role in the West German Study Group and the European Society for Medical Oncology. S.-A.I. has received grants from Daiichi Sankyo, AstraZeneca, Eisai, Daewoong Pharm, Pfizer, Roche and Boryung Pharm; has received consulting fees from Daiichi Sankyo, AstraZeneca, Hanmi, Eisai, Lilly, MSD, Idience, Novartis, Pfizer, Roche, GSK and Bertis. M.D.L. has received honoraria from Daiichi Sankyo, Eli Lilly, Novartis, Seagen, Takeda, Roche, Tomalab, Gilead, Genetic, Menarini and Sophos; has received support for attending meetings and/or traveling from Gilead, Novartis, Roche and AstraZeneca; participated on a data safety monitoring or advisory board for Pfizer, Daiichi Sankyo, AstraZeneca, Sanofi, Seagen, Novartis, Ipsen, Roche, Pierre Fabre and GSK. J.-Y.P. has received consulting fees from Daiichi Sankyo, AstraZeneca, MSD and Gilead; has received honoraria from Daiichi Sankyo, AstraZeneca, MSD, Lilly, Pfizer, Novartis, Roche, Exact Science and Gilead; has received support for attending meetings and/or travel from AstraZeneca, Eisai, Roche and Pfizer; has participated in a data safety monitoring or advisory board for Sanofi and Novartis. A.G. has received honoraria from Daiichi Sankyo, AstraZeneca, MSD and Roche; has received support for attending meetings and/or travel from Daiichi Sankyo, AstraZeneca and Gilead; has a leadership or fiduciary role on the advisory boards for AstraZeneca, Seagen and Lilly. E.T. has received honoraria from Daiichi Sankyo, AstraZeneca and Eli Lilly. D.C. has received honoraria from Aptitude Health, Roche, Pfizer, Celldex Therapeutics, Carnall Farrar, San Antonio Breast Cancer Consortium, Highfield Communication, AstraZeneca, Global Commercial Organisation—Egypt, Celgene, Chief Scientists Office, Cancer Research UK, HTA, Samsung Bioepis, Eli Lilly, Costello Medical, prIME Oncology, Novartis, PFS, Merck, Puma, F. Hoffmann-La Roche, Clovis Oncology Breast International Group, Breast Cancer Institute, Daiichi Sankyo, Eisai, Elsevier, European Cancer Organisation, Exact Therapeutics, G1 Therapeutics, Galapagos NV, Genentech Inc., GSK (GlaxoSmithKline), ICON Clinical Research, Prima BioMED, RTI Health Solutions, Seattle Genetics, Byondis, Succinct Medical Communications, Seagen, Sanofi, Sapience Therapeutics, Bexon/Zymeworks Biopharmaceuticals, Make Seconds Count, NexGen and IQVIA. C.O.A., L.Y., F.X. and Y.C. are employed by Daiichi Sankyo and have received stock and other ownership interests from Daiichi Sankyo. The other authors declare no competing interests.
